Delaware Supreme Court Heard Arguments Over Vividion Sale
The court examined claims that Bayer AG underpaid for the biotech firm due to a missing patent.
Updated on Sept. 23, 2026 in Healthcare
Live Poll
Do you trust that courts effectively ensure fair pricing in large corporate acquisitions?
The Delaware Supreme Court heard oral arguments in a case challenging the $2 billion acquisition price of Vividion Therapeutics. Cardinal Partners contends the firm would have fetched a higher price if a specific patent had been included in the sale to Bayer AG.
Why it matters
The case, CHP III LP v. Cravatt, highlights disputes over intellectual property valuations during high-stakes corporate acquisitions. It questions whether the full scope of a company's assets was adequately accounted for during the $2 billion buyout by Bayer AG.
Bayer AG acquired Vividion Therapeutics for $2 billion. The litigation centers on whether this transaction undervalued the company due to intellectual property disputes.
The players
Bayer AG
Bayer AG is a German multinational pharmaceutical and biotechnology company that acquired Vividion Therapeutics.
Cardinal Partners
Cardinal Partners is the firm challenging the acquisition price of Vividion Therapeutics in court.
Vividion Therapeutics
Vividion Therapeutics is a biotechnology company that was the subject of a $2 billion acquisition by Bayer AG.
Delaware Supreme Court
The Delaware Supreme Court is the highest judicial body in the state and is presiding over case number 70,2026.
The details
Cardinal Partners argues that Bayer AG would have paid a premium for the company if it had secured control of a specific patent. The Delaware Supreme Court is currently reviewing the legal claims to determine if the acquisition terms were fair to shareholders.
Timeline
The Delaware Supreme Court held oral arguments on September 23, 2026.
Market Landscape
This litigation follows a well-established pattern of Delaware corporate law disputes regarding the rigorous valuation of intellectual property during major acquisitions. It demonstrates how judicial oversight in the state remains a critical check on the acquisition processes used by global pharmaceutical giants.
This case has little direct impact on the day-to-day operations or drug prices for patients using products from Bayer AG. It primarily serves as a high-level corporate dispute regarding the fair market valuation of biotech research assets between investment entities.
The takeaway
The case underscores the necessity of precise intellectual property auditing before finalizing multi-billion dollar biotech deals. Investors should note how patent ownership remains a primary driver of valuation disputes in the pharmaceutical sector.
Further reading
Learn more about legal developments in the industry on the Healthcare section.
Source note: This article includes information reported by Bloomberglaw.
Live Poll
Do you trust that courts effectively ensure fair pricing in large corporate acquisitions?
